Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | IL1RN | P18510 | 1/20 | 0.52 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.52 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.52 |
| ▸ | CTSB | P07858 | 3/20 | 0.50 |
| ▸ | CTSK | P43235 | 2/20 | 0.50 |
| ▸ | CTSL | P07711 | 1/20 | 0.49 |
| ▸ | CTSS | P25774 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | ELANE | P08246 | 2/20 | 0.47 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8707008 | 1.00 | ALDH1A1 (0.53) | ALDH1A1IL1RNERAP2ERAP1CTSB | |
| Hydrochloric Acid SCHEMBL8712756 | 0.98 | ALDH1A1 (0.51) | ALDH1A1IL1RNERAP2ERAP1CTSB | |
| Hydrochloric Acid SCHEMBL25265036 | 0.98 | ALDH1A1 (0.51) | ALDH1A1IL1RNERAP2ERAP1CTSB | |
| SCHEMBL13046576 | 0.90 | ALDH1A1 (0.46) | ALDH1A1IL1RNERAP2ERAP1CTSB | |
| SCHEMBL8346888 | 0.89 | CTSL (0.54) | ALDH1A1IL1RNERAP2ERAP1CTSB | |
| SCHEMBL8347270 | 0.89 | CTSL (0.54) | ALDH1A1IL1RNERAP2ERAP1CTSB | |
| SCHEMBL8228565 | 0.87 | ALDH1A1 (0.53) | ALDH1A1IL1RNERAP2ERAP1CTSB | |
| SCHEMBL20804193 | 0.86 | MMP9 (0.52) | ALDH1A1IL1RNERAP2ERAP1CTSB | |
| SCHEMBL22346387 | 0.86 | CTSL (0.56) | ALDH1A1CTSBCTSKCTSLCTSS | |
| SCHEMBL22346389 | 0.86 | CTSL (0.56) | ALDH1A1CTSBCTSKCTSLCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002316-A1 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS | PIERRE FABRE MEDICAMENT (FR) | 2023-01-05 | — | — | US | disclosed |
| US-11517625-B2 | Antibody-drug-conjugate and its use for the treatment of cancer | PIERRE FABRE MEDICAMENT (FR) | 2022-12-06 | — | — | US | disclosed |
| US-11219693-B2 | Antibody-drug-conjugate and its use for the treatment of cancer | PIERRE FABRE MEDICAMENT (FR) | 2022-01-11 | — | — | US | disclosed |
| US-20210107868-A1 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS | PIERRE FABRE MEDICAMENT (FR) | 2021-04-15 | — | — | US | disclosed |
| US-20210038738-A1 | ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | PIERRE FABRE MEDICAMENT (FR) | 2021-02-11 | — | — | US | disclosed |
| US-10912841-B2 | Antibody-drug-conjugate and its use for the treatment of cancer | PIERRE FABRE MEDICAMENT (FR) | 2021-02-09 | — | — | US | disclosed |
| US-10858423-B2 | Composition for the treatment of IGF-1R expressing cancer | PIERRE FABRE MEDICAMENT (FR) | 2020-12-08 | — | — | US | disclosed |
| US-20200270352-A1 | IGF-1R ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | PIERRE FABRE MEDICAMENT (FR) | 2020-08-27 | — | — | US | disclosed |
| US-10633448-B2 | IGF-1R antibody-drug-conjugate and its use for the treatment of cancer | PIERRE FABRE MEDICAMENT (FR) | 2020-04-28 | — | — | US | disclosed |
| EP-3134125-B1 | ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | PF MEDICAMENT (FR) | 2019-10-09 | — | — | EP | disclosed |
| US-20190202901-A1 | COMPOSITION FOR THE TREATMENT OF IGF-1R EXPRESSING CANCER | PIERRE FABRE MEDICAMENT (FR) | 2019-07-04 | — | — | US | disclosed |
| US-10314921-B2 | Antibody-drug-conjugate and its use for the treatment of cancer | PIERRE FABRE MEDICAMENT (FR) | 2019-06-11 | — | — | US | disclosed |
| US-20180222858-A1 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS | PIERRE FABRE MEDICAMENT (FR) | 2018-08-09 | — | — | US | disclosed |
| US-9669106-B2 | Conjugate of monomethyl auristatin F and trastuzumab and its use for the treatment of cancer | PIERRE FABRE MEDICAMENT (FR) | 2017-06-06 | — | — | US | disclosed |
| US-20170112943-A1 | CONJUGATE OF MONOMETHYL AURISTATIN F AND TRASTUZUMAB AND ITS USE FOR THE TREATMENT OF CANCER | PIERRE FABRE MEDICAMENT (FR) | 2017-04-27 | — | — | US | disclosed |
| US-20170043032-A1 | ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | PIERRE FABRE MEDICAMENT (FR) | 2017-02-16 | — | — | US | disclosed |
| EP-1329160-A2 | 4-ACYLAMINOPYRAZOLE DERIVATIVES | Sankyo Company, Limited (JP) | 2003-07-23 | — | — | EP | disclosed |
| US-5739104-A | CYCLIC PEPTIDES | SCHERING CORPORATION (US) | 1998-04-14 | — | — | US | disclosed |
| EP-0760822-A1 | ANTI-FUNGAL CYCLIC DEPSIPEPTIDES | SCHERING CORPORATION (US) | 1997-03-12 | — | — | EP | disclosed |
| WO-1995030692-A1 | ANTI-FUNGAL CYCLIC DEPSIPEPTIDES | SCHERING CORPORATION (US) | 1995-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10858423-B2 | Composition for the treatment of IGF-1R expressing cancer | IGF1R, IGFBP1, IGFBP5 | ALDH1A1 532/4885IL1RN 64/4885ERAP2 4144/4885 |
| US-20170043032-A1 | ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | KRTCAP2, DDOST, DAD1 | ALDH1A1 982/4885IL1RN 1844/4885ERAP2 2131/4885 |
| US-20200270352-A1 | IGF-1R ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | IGF1R, IGFBP1, IGFBP5 | ALDH1A1 839/4885IL1RN 33/4885ERAP2 4166/4885 |
| US-20170112943-A1 | CONJUGATE OF MONOMETHYL AURISTATIN F AND TRASTUZUMAB AND ITS USE FOR THE TREATMENT OF CANCER | AURKC, AURKA, EGFR | ALDH1A1 1383/4885IL1RN 1807/4885ERAP2 2139/4885 |
| US-10912841-B2 | Antibody-drug-conjugate and its use for the treatment of cancer | DDOST, DAD1, KRTCAP2 | ALDH1A1 1223/4885IL1RN 1732/4885ERAP2 1557/4885 |
| US-10633448-B2 | IGF-1R antibody-drug-conjugate and its use for the treatment of cancer | IGF1R, IGFBP1, IGFBP5 | ALDH1A1 839/4885IL1RN 33/4885ERAP2 4166/4885 |
| US-20180222858-A1 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS | NR1H4, HCAR3, VDR | ALDH1A1 2916/4885IL1RN 1516/4885ERAP2 3918/4885 |
| US-11517625-B2 | Antibody-drug-conjugate and its use for the treatment of cancer | DDOST, DAD1, KRTCAP2 | ALDH1A1 1223/4885IL1RN 1732/4885ERAP2 1557/4885 |
| US-20230002316-A1 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS | NR1H4, HCAR3, VDR | ALDH1A1 2916/4885IL1RN 1516/4885ERAP2 3918/4885 |
| US-11219693-B2 | Antibody-drug-conjugate and its use for the treatment of cancer | DAD1, DDOST, KRTCAP2 | ALDH1A1 949/4885IL1RN 1680/4885ERAP2 2020/4885 |
| US-20190202901-A1 | COMPOSITION FOR THE TREATMENT OF IGF-1R EXPRESSING CANCER | IGF1R, IGFBP1, IGFBP5 | ALDH1A1 532/4885IL1RN 64/4885ERAP2 4144/4885 |
| US-20210038738-A1 | ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | DDOST, DAD1, KRTCAP2 | ALDH1A1 1110/4885IL1RN 1700/4885ERAP2 1633/4885 |
| US-20210107868-A1 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS | NR1H4, HCAR3, VDR | ALDH1A1 2916/4885IL1RN 1516/4885ERAP2 3918/4885 |
| US-10314921-B2 | Antibody-drug-conjugate and its use for the treatment of cancer | KRTCAP2, DDOST, DAD1 | ALDH1A1 982/4885IL1RN 1844/4885ERAP2 2131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.